Why It Matters

ConvaTec faces a threat to business after CMS cut Medicare reimbursement for skin substitutes by approximately 90 percent in late 2025—dropping payments from over $1,000 per treatment to $125. The wound care industry mobilized on Capitol Hill in response. ConvaTec and competitors are collectively spending millions to push companion bills (S. 2561 / H.R. 5768) that would establish a statutory payment framework for skin substitutes.

What’s at stake is whether Congress will override administratively-determined Medicare rates—setting a precedent for legislative pushback against executive healthcare payment decisions. ConvaTec’s strategy leverages Holland & Knight’s healthcare expertise and lobbyists with direct congressional experience, including Jordan K. Brossi’s recent work as Health Policy Adviser to Rep. Anna Eshoo (D-CA).

By the Numbers

ConvaTec Advanced Tissue Technologies has invested $880,000 in federal lobbying since June 2022, exclusively retaining Holland & Knight LLP. The company spent $80,000 in the last quarter on Medicare wound care reform.

ConvaTec strengthened its advocacy roster by adding Jordan K. Brossi, who previously worked as Health Policy Adviser for Rep. Anna Eshoo (D-CA-16) and held staff positions with Sen. Tammy Baldwin (D-WI) and Sen. Joe Manchin (D-WV). Miranda A. Franco, a veteran healthcare lobbyist with over a decade of regenerative medicine expertise, continues representing ConvaTec.

Notably, Brossi also represents Acesso Biologics on identical legislative priorities, indicating concentrated industry coordination.

The Agenda

ConvaTec is lobbying specifically on the Skin Substitute Access & Payment Reform Act (S. 2561 / H.R. 5768). The companion bills, introduced by Senator Bill Cassidy (R-LA) and Representative Buddy Carter (R-GA), aim to standardize Medicare payment methodologies for skin substitute products. ConvaTec is part of a broader industry coalition—including Organogenesis Inc. and Acesso Biologics—all advocating for this legislative reform.

Broader Context

Medicare spending on skin substitutes surged from $256 million in 2019 to over $10 billion in 2024, prompting the HHS Office of Inspector General to raise "major concerns" about fraud, waste, and abuse. In 2025 alone, CMS stopped nearly $185 million in improper payments.

CMS’s dramatic payment cuts effective 2026 reclassify skin substitutes as "incident-to supplies", directly threatening the industry’s revenue base. This coordinated industry response signals an existential threat driving synchronized congressional engagement.

Between The Lines

Senator Bill Cassidy introduced S. 2561 on July 31, 2025, proposing standardized volume-weighted average payment methodology effective January 1, 2026. Representative Buddy Carter introduced the House companion bill, H.R. 5768, on October 17, 2025. Both bills were referred to their respective committees of jurisdiction.

Individual members have demonstrated growing interest in advanced wound care technology. Representative Mariannette Miller-Meeks (R-IA-1) toured wound treatment facilities, while Representative Gary Palmer (R-AL-6) visited an Organogenesis facility, suggesting expanding congressional awareness.

Competitive Landscape

ConvaTec is part of a substantial industry coalition. Acesso Biologics spent $50,000 in Q4 2025 on the same legislation, sharing lobbyist Jordan K. Brossi with ConvaTec. Organogenesis Inc. spent $300,000 in Q3 2025 on in-house lobbying. bioCARE Donor Tissue Network invested $750,000 total across 2025.

This coordinated effort represents millions in combined spending to reshape federal reimbursement policy.

The Bottom Line

ConvaTec’s $880,000 lobbying investment since 2022 targets the Skin Substitute Access & Payment Reform Act as part of a broader industry coalition spending millions to challenge CMS’s dramatic payment cuts. The company’s sustained commitment through Holland & Knight LLP reflects the wound care industry’s fight for survival against aggressive federal cost-containment measures.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article